MMSL 2016, 85(1):31-38 | DOI: 10.31482/mmsl.2016.005

CARDIAC MULTIMARKER TESTING IN NON-OBSTRUCTIVE HYPERTROPHIC CARDIOMYOPATHYOriginal article

Radek Pudil1*, Martina Vašatová2, Alena Myslivcová Fučíková ORCID...3, Helena Řehulková ORCID...3, Pavel Řehulka ORCID...3, Vladimír Palička2, Jiří Stulík ORCID...3
1 1st Department of Internal Medicine - Cardioangiology, Charles University Prague, Faculty of Medicine in Hradec Králové, Czech Republic
2 Institute of Clinical Biochemistry and Diagnostics, University Hospital in Hradec Králové, Czech Republic
3 Department of Molecular Pathology and Biology, Faculty of Military Health Sciences, University of Defense, Hradec Králové, Czech Republic

The natural history of hypertrophic cardiomyopathy (HCM) varies from an asymptomatic and benign clinical course to sudden premature death. Therefore, the new markers are searched with the aim to detect risk patients and improve their prognosis. The aim of this study was to test a cardiac multimarker testing strategy in detection of initial structural changes in patients with nonobstructive hypertrophic cardiomyopathy (HCM). In the group of 47 patients with nonobstructive HCM (58.4 ± 12.4 years, 12 emales) the mean left ventricle mass was 344.8 ± 129.9 g, the mean left ventricle mass index was 171.4 ± 60.2 g.m-2. We observed increased concentration of cardiac markers in peripheral blood: high sensitivity troponin T (hsTnT): median: 9 ng/L (IQR: 5 - 16 ng/L), vs. controls: 7 (5 - 9) ng/L, p 0.03; creatine kinase MB isoenzyme (CK MB): 2 (1.4 - 2.7) μg/L vs. 1.6 (1.1 - 2.2) μg/L, p 0.04; myoglobin 46.4 (33.3 - 65.2) μg/L vs. 35.6 (22.8 - 43.7) μg/L, p 0.001; heart type of fatty acid binding protein (hFABP): 1.8 (1.4 - 3.3) μg/L vs. 1.6 (1.3 - 2.1) μg/L, p 0.05; glycogen phosphorylase BB (GPBB): 3.9 (2.5 - 6.3) μg/L vs. 2.3 (1.9 - 4.2) μg/L, p 0.001. The analysis of the associations of left ventricle mass index and cardiac markers revealed its significant association with hFABP (r = 0.41, 95% CI: 0.07-0.66, p 0.01), CKMB (r = 0.33, 95% CI: 0.11-0.59, p 0.05), and with hsTnT (r = 0.39, 95%CI: 0.12 - 0.62, p 0.008). This study indicates potential clinical use of the multimarker testing in diagnosis and screening of the hypertrophic cardiomyopathy.

Keywords: cardiac markers; hypertrophic cardiomyopathy; morphology

Received: January 18, 2016; Revised: February 14, 2016; Published: March 4, 2016  Show citation

ACS AIP APA ASA Harvard Chicago Chicago Notes IEEE ISO690 MLA NLM Turabian Vancouver
Pudil, R., Vašatová, M., Myslivcová Fučíková, A., Řehulková, H., Řehulka, P., Palička, V., & Stulík, J. (2016). CARDIAC MULTIMARKER TESTING IN NON-OBSTRUCTIVE HYPERTROPHIC CARDIOMYOPATHY. MMSL, 85(1), 31-38. doi: 10.31482/mmsl.2016.005
Share...
Download citation
  • BibTeX (.bib)
  • Bookends (.ris)
  • EasyBib (.ris)
  • EndNote (.enw)
  • EndNote 8 (.xml)
  • ISI WoS (.isi)
  • Medlars (.medlars)
  • Mendeley (.ris)
  • MODS (.xml)
  • Papers (.ris)
  • RefWorks (.txt)
  • RefManager (.ris)
  • RIS (.ris)
  • MS Word (.xml)
  • Zotero (.ris)
    • Open full article

    References

    1. Gersh, B.J.; Maron, B.J.; Bonow, R.O.; Dearani, J.A.; Fifer, M.A.; Link, M.S.; Naidu, S.S.; Nishimura, R.A.; Ommen, S.R.; Rakowski, H.; Seidman, C.E.; Towbin, J.A.; Udelson, J.E.; Yancy, C.W. et al. 2011 ACCF/AHA Guideline for the Diagnosis and Treatment of Hypertrophic Cardiomyopathy: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. Am. Coll. Cardiol. 2011, 58 (25), e212-60. Go to original source... Go to PubMed...
    2. Elliott. P.M.; Anastasakis, A.; Borger, M.A.; Borggrefe, M.; Cecchi, F.; Charron, P.; Hagege, A.A.; Lafont, A.; Limongelli, G.; Mahrholdt, H.; McKenna, W.J.; Mogensen, J.; Nihoyannopoulos, P.; Nistri, S.; Pieper, P.G.; Pieske, B.; Rapezzi, C.; Rutten, F.H.; Tillmanns, C.; Watkins, H. 2014 ESC Guidelines on diagnosis and management of hypertrophic cardiomyopathy: the Task Force for the Diagnosis and Management of Hypertrophic Cardiomyopathy of the European Society of Cardiology (ESC). Eur. Heart J. 2014, 35 (39), 2733-79.
    3. Panteghini, M. Role and importance of biochemical markers in clinical cardiology. Eur. Heart J. 2004, 25, 1187-96. Go to original source... Go to PubMed...
    4. Shibuya, M. Vascular endothelial growth factor and its receptor system: physiological functions in angiogenesis and pathological roles in various diseases. J. Biochem. 2013, 153 (1), 13 - 19. Go to original source... Go to PubMed...
    5. Cambronero, F.; Marin, F.; Roldan, V.; Hernandez-Romero, D.; Valdes, M.; Lip, G.Y. Biomarkers of pathophysiology in hypertrophic cardiomyopathy: implications for clinical management and prognosis. Eur. Heart J. 2009, 30 (2), 139 - 51. Go to original source... Go to PubMed...
    6. Kubo, T.; Kitaoka, H.; Yamanaka, S.; Hirota, T.; Baba, Y.; Hayashi, K.; Iiyama, T.; Kumagai, N.; Tanioka, K.; Yamasaki, N.; Matsumura, Y.; Furuno, T.; Sugiura, T. Doi YL. Significance of high-sensitivity cardiac troponin T in hypertrophic cardiomyopathy. J. Am. Coll. Cardiol. 2013, 62 (14), 1252-9. Go to original source... Go to PubMed...
    7. Maron, B.J.; Tholakanahalli, V.N.; Zenovich, A.G.; Casey, S.A.; Duprez, D.; Aeppli, D.M.; Cohn, J.N. Usefulness of B-type natriuretic peptide assay in the assessment of symptomatic state in hypertrophic cardiomyopathy. Circulation. 2004, 109, 984 - 989. Go to original source... Go to PubMed...
    8. Kuusisto, J. Significance of plasma levels of N-Terminal pro-B-type natriuretic peptide on left ventricular remodeling in non-obstructive hypertrophic cardiomyopathy attributable to the Asp175Asn mutation in the tropomyosin gene. Am. J. Cardiol. 2008, 101, 1185 - 1190.
    9. Okawa, M.; Kitaoka, H.; Matsumura, Y.; Kubo, T.; Yamasaki, N.; Furuno, T. Doi Y. Functional assessment by myocardial performance index (Tei index) correlates with plasma brain natriuretic peptide concentration in patients with hypertrophic cardiomyopathy. Circ. J. 2005, 69, 951 - 957. Go to original source... Go to PubMed...
    10. Matsuura, H.; Murakami, T.; Hina, K.; Yamamoto, K.; Kawamura, H.; Sogo, T.; Shinohata, R.; Usui, S.; Ninomiya, Y.; Kusachi S. Association of elevated plasma B-type natriuretic peptide levels with paroxysmal atrial fibrillation in patients with nonobstructive hypertrophic cardiomyopathy. Clin. Biochem. 2008, 41, 134 - 139. Go to original source... Go to PubMed...
    11. Houston, B.A.; Stevens, G.R. Hypertrophic Cardiomyopathy: A Review. Clin. Med. Insights Cardiol. 2014, 8 (Suppl 1), 53 - 65. Go to original source... Go to PubMed...
    12. Lang, R.M.; Badano, L.P.; Mor-Avi, V.; Afilalo, J.; Armstrong, A.; Ernande, L.; Flachskampf, F.A.; Foster, E.; Goldstein, S.A.; Kuznetsova, T.; Lancellotti, P.; Muraru, D.; Picard, M.H.; Rietzschel, E.R.; Rudski, L.; Spencer, K.T.; Tsang, W.; Voigt, J.U. Recommendations for cardiac chamber quantification by echocardiography in adults: an update from the American Society of Echocardiography and the European Association of Cardiovascular Imaging. Eur. Heart J. Cardiovasc. Imaging. 2015, 16 (3), 233 - 70. Go to original source... Go to PubMed...
    13. Colli, A.; Josa, M.; Pomar, J.L.; Mestres, C.A.; Gherli, T. Heart fatty acid binding protein in the diagnosis of myocardial infarction: where do we stand today? Cardiology. 2007, 108, 4-10. Go to original source... Go to PubMed...
    14. Peetz, D.; Post, F.; Schnitzel, H. Glycogen phosphorylase BB in acute coronary syndromes. Clin. Chem. Lab. Med. 2005, 43,1351-8. Go to original source... Go to PubMed...

    Return to the content